Skip to content

Autophagy and Venous Endothelial Function

Impact of Reactivation of Autophagy Through Spermidine on Venous Endothelial Function

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT04138134
Enrollment
200
Registered
2019-10-24
Start date
2022-02-01
Completion date
2023-04-01
Last updated
2023-02-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Venous Disease

Keywords

autophagy, spermidine

Brief summary

The molecular mechanisms involved in venous endothelial dysfunction are largely unknowns. Autophagy is an intracellular mechanism devoted to the removal of damaged cytoplasmic elements. Previous evidence demonstrated that activation of autophagy exerts beneficial effects in the cardiovascular system, reducing cardiac damage and improving cardiac function in response to stress. However, the association between venous endothelial dysfunction and autophagy remains to be characterized. In this study the investigators will test whether reactivation of autophagy through a natural compound (spermidine) is able to improve vascular function in saphenous veins derived from patients subjected to saphenectomy. The same outcome will be evaluated in saphenous veins isolated from patients with atherosclerotic obstructive disease of the lower limbs subjected revascularization through implantation of venous by-pass.

Detailed description

Endothelial dysfunction contributes to different cardiovascular diseases, such as atherosclerosis, myocardial infarction, stroke and peripheral artery diseases. Recent evidence also demonstrated that endothelial dysfunction is associated with vascular venous diseases. In this regard, venous endothelial dysfunction contributes to the development of varicose veins and deep vein thrombosis. Disequilibrium in endothelial function is also present in venous traits derived from saphenous veins which are routinely used as aortocoronary by-pass. The molecular mechanisms involved in venous diseases require further investigations. Autophagy, the intracellular mechanism devoted to the removal of dysfunctional or senescent cytoplasmic elements may represent a new therapeutic target for the treatment of vascular diseases. In this regard, it has been demonstrated that the enhancement of autophagy limits cardiac injury in pre-clinical models of cardiovascular diseases. However, the association between autophagy and vascular disease is still unknown in humans. Spermidine is a natural activator of autophagy which has been demonstrated to extend lifespan in mice and to reduce cardiac dysfunction through autophagy-dependent mechanisms. The objectives of this study will be the following: 1) to test whether spermidine is able to improve vascular function and to reduce oxidative stress in saphenous veins obtained from patients subjected to saphenectomy due to chronic venous insufficiency or varicose veins; 2) to test whether spermidine is able to improve vascular function in saphenous veins derived from patients with atherosclerotic obstructive disease of lower limbs subjected to revascularization through implantation of arteriosus by-pass. In a different set of experiments, the investigators will also test whether vein portions incubated with spermidine show increased autophagy and decreased markers of oxidative stress with respect to controls. The investigators expect that venous segments treated with spermidine will show an amelioration of endothelial function

Interventions

None listed

Sponsors

Principal investigator: Giacomo Frati
CollaboratorUNKNOWN
Co-investigator: Francesco Pompeo
CollaboratorUNKNOWN
Neuromed IRCCS
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
18 Years to 85 Years

Inclusion criteria

* Eligible subjects undergoing saphenectomy * Patients with chronic venous insufficiency * Patients with varicose veins * Eligible subjects undergoing peripheral artery revascularization through implantation of venous by-pass derived from saphenous vein * Acceptance and signature of the informed consent

Exclusion criteria

* Chronic and acute Inflammatory diseases * Immunological and rheumatic diseases * Pre-existing or ongoing neoplasms * Infectious diseases * Previous organ transplantation * Treatment with pharmacological therapies able to modulate autophagy, i. e. rapamycin and derivative compounds (rapalogues). * Antioxidant therapies in the last three months * Patients with surgical technical complications

Design outcomes

Primary

MeasureTime frameDescription
Evaluation of endothelial function in venous samples from patients with venous insufficiency before and after treatment with autophagy enhancer spermidineImmediately after the samplingEx vivo vascular reactivity experiments performed on isolated veins treated or not with spermidine ex vivo.

Secondary

MeasureTime frameDescription
Impact of autophagy on endothelial venous function6 monthsQuantification by immunoblot of markers of autophagy (LC3, p62, Beclin1, Atg5, Atg7, Ulk1) and its statistical correlation with venous endothelial function
Correlation between autophagy, oxidative stress and endothelial function6 monthsQuantification by immunoblot of markers of autophagy and oxidative stress and statistical correlation with venous endothelial function

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026